Advanced glycation end products modulate amyloidogenic APP processing and Tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer’s disease

Kedar Batkulwar, Rashmi Godbole, Reema Banarjee, Omar Kassaar, Robert J Williams, Mahesh Kulkarni

Research output: Contribution to journalArticle

16 Citations (Scopus)
32 Downloads (Pure)

Abstract

Advanced glycation end products (AGEs) are implicated in the pathology of Alzheimer's disease (AD), as they induce neurodegeneration following interaction with the receptor for AGE (RAGE). This study aimed to establish a mechanistic link between AGE-RAGE signaling and AD pathology. AGE-induced changes in the neuro2a proteome were monitored by SWATH-MS. Western blotting and cell-based reporter assays were used to investigate AGE-RAGE regulated APP processing and tau phosphorylation in primary cortical neurons. Selected protein expression was validated in brain samples affected by AD. The AGE-RAGE axis altered proteome included increased expression of cathepsin B and asparagine endopeptidase (AEP), which mediated an increase in Aβ 1-42 formation and tau phosphorylation, respectively. Elevated cathepsin B, AEP, RAGE, and pTau levels were found in human AD brain, coincident with enhanced AGEs. This study demonstrates that the AGE-RAGE axis regulates Aβ 1-42 formation and tau phosphorylation via increased cathepsin B and AEP, providing a new molecular link between AGEs and AD pathology.

Original languageEnglish
Pages (from-to)988-1000
Number of pages13
JournalACS Chemical Neuroscience
Volume9
Issue number5
Early online date31 Jan 2018
DOIs
Publication statusPublished - 16 May 2018

Fingerprint

Advanced Glycosylation End Products
Phosphorylation
Alzheimer Disease
Endopeptidases
Cathepsin B
Asparagine
Pathology
Processing
Proteome
Brain
Neurons
Advanced Glycosylation End Product-Specific Receptor
Assays
Western Blotting
Proteins

Keywords

  • Advanced glycation end products
  • Alzheimer’s disease

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Advanced glycation end products modulate amyloidogenic APP processing and Tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer’s disease. / Batkulwar, Kedar; Godbole, Rashmi ; Banarjee, Reema ; Kassaar, Omar; Williams, Robert J; Kulkarni, Mahesh.

In: ACS Chemical Neuroscience, Vol. 9, No. 5, 16.05.2018, p. 988-1000.

Research output: Contribution to journalArticle

@article{1f6b1d127b7b4c76a6b7804e45b59bd2,
title = "Advanced glycation end products modulate amyloidogenic APP processing and Tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer’s disease",
abstract = "Advanced glycation end products (AGEs) are implicated in the pathology of Alzheimer's disease (AD), as they induce neurodegeneration following interaction with the receptor for AGE (RAGE). This study aimed to establish a mechanistic link between AGE-RAGE signaling and AD pathology. AGE-induced changes in the neuro2a proteome were monitored by SWATH-MS. Western blotting and cell-based reporter assays were used to investigate AGE-RAGE regulated APP processing and tau phosphorylation in primary cortical neurons. Selected protein expression was validated in brain samples affected by AD. The AGE-RAGE axis altered proteome included increased expression of cathepsin B and asparagine endopeptidase (AEP), which mediated an increase in Aβ 1-42 formation and tau phosphorylation, respectively. Elevated cathepsin B, AEP, RAGE, and pTau levels were found in human AD brain, coincident with enhanced AGEs. This study demonstrates that the AGE-RAGE axis regulates Aβ 1-42 formation and tau phosphorylation via increased cathepsin B and AEP, providing a new molecular link between AGEs and AD pathology.",
keywords = "Advanced glycation end products, Alzheimer’s disease",
author = "Kedar Batkulwar and Rashmi Godbole and Reema Banarjee and Omar Kassaar and Williams, {Robert J} and Mahesh Kulkarni",
year = "2018",
month = "5",
day = "16",
doi = "10.1021/acschemneuro.7b00410",
language = "English",
volume = "9",
pages = "988--1000",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Advanced glycation end products modulate amyloidogenic APP processing and Tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer’s disease

AU - Batkulwar, Kedar

AU - Godbole, Rashmi

AU - Banarjee, Reema

AU - Kassaar, Omar

AU - Williams, Robert J

AU - Kulkarni, Mahesh

PY - 2018/5/16

Y1 - 2018/5/16

N2 - Advanced glycation end products (AGEs) are implicated in the pathology of Alzheimer's disease (AD), as they induce neurodegeneration following interaction with the receptor for AGE (RAGE). This study aimed to establish a mechanistic link between AGE-RAGE signaling and AD pathology. AGE-induced changes in the neuro2a proteome were monitored by SWATH-MS. Western blotting and cell-based reporter assays were used to investigate AGE-RAGE regulated APP processing and tau phosphorylation in primary cortical neurons. Selected protein expression was validated in brain samples affected by AD. The AGE-RAGE axis altered proteome included increased expression of cathepsin B and asparagine endopeptidase (AEP), which mediated an increase in Aβ 1-42 formation and tau phosphorylation, respectively. Elevated cathepsin B, AEP, RAGE, and pTau levels were found in human AD brain, coincident with enhanced AGEs. This study demonstrates that the AGE-RAGE axis regulates Aβ 1-42 formation and tau phosphorylation via increased cathepsin B and AEP, providing a new molecular link between AGEs and AD pathology.

AB - Advanced glycation end products (AGEs) are implicated in the pathology of Alzheimer's disease (AD), as they induce neurodegeneration following interaction with the receptor for AGE (RAGE). This study aimed to establish a mechanistic link between AGE-RAGE signaling and AD pathology. AGE-induced changes in the neuro2a proteome were monitored by SWATH-MS. Western blotting and cell-based reporter assays were used to investigate AGE-RAGE regulated APP processing and tau phosphorylation in primary cortical neurons. Selected protein expression was validated in brain samples affected by AD. The AGE-RAGE axis altered proteome included increased expression of cathepsin B and asparagine endopeptidase (AEP), which mediated an increase in Aβ 1-42 formation and tau phosphorylation, respectively. Elevated cathepsin B, AEP, RAGE, and pTau levels were found in human AD brain, coincident with enhanced AGEs. This study demonstrates that the AGE-RAGE axis regulates Aβ 1-42 formation and tau phosphorylation via increased cathepsin B and AEP, providing a new molecular link between AGEs and AD pathology.

KW - Advanced glycation end products

KW - Alzheimer’s disease

UR - http://www.scopus.com/inward/record.url?scp=85047158077&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.7b00410

DO - 10.1021/acschemneuro.7b00410

M3 - Article

VL - 9

SP - 988

EP - 1000

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 5

ER -